GLP-1 & Incretin Science

Blocking and Activating the Same Receptor, in One Model

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Davies and colleagues published a metabolic comparison of GIP receptor agonism against antagonism in male mice in Diabetes, Obesity and Metabolism in February 2026. The first time the two opposing strategies have been tested side by side in one model rather than inferred across separate human trials.

Key facts

Direct comparison
Davies 2026 (PMID 41287212)
Model
Male mice
Agonism example
Tirzepatide (with GLP-1 agonism)
Antagonism example
Maridebart cafraglutide
Case for agonism
Samms 2025 (PMID 40521890)
Human question
Still unresolved

Why the paradox exists at all

Tirzepatide activates the GIP receptor and produces substantial weight reduction. Maridebart cafraglutide blocks the same receptor and also produces substantial weight reduction. Both are paired with GLP-1 receptor agonism. Opposite manipulations of one target apparently producing the same directional outcome is the kind of result that indicates something in the model is wrong.

Why the existing evidence could not settle it

Every comparison until now was across trials. Different compounds, different formats, different doses, different populations, different durations. Cross-trial comparison cannot attribute a difference to the receptor when everything else differs too. That is the same structural problem that makes head-to-heads necessary in the clinical literature.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What a matched preclinical comparison adds

One species, one model, both directions, conditions held constant. Davies and colleagues compared the metabolic consequences of agonism and antagonism in male mice, which is the design that can actually isolate the variable. It is the right experiment for the question even though it is not in humans.

The candidate explanations it can discriminate between

Several have been proposed. That sustained agonism desensitises the receptor, making chronic agonism functionally equivalent to blockade. That the two act in different tissues (central versus adipose) with opposite roles. That GIP receptor manipulation in either direction mainly modulates tolerability of the GLP-1 component rather than driving weight loss itself. A matched comparison produces data these hypotheses predict differently.

The case for agonism, stated by its proponents

Samms and colleagues published a contemporary rationale for GIP receptor agonism in obesity in Diabetes in August 2025. Reading it alongside the antagonist clinical programme is the honest way to hold this question, two serious arguments, both with supporting data, and no resolution yet.

What a mouse study does not settle

The human question. Rodent metabolic physiology differs from human in ways that matter for incretin biology specifically, and compounds behave differently across species. This narrows the hypothesis space; it does not tell you which clinical strategy is better, and only a human head-to-head could.

Frequently asked questions

How can blocking and activating a receptor both cause weight loss?

That is the paradox. Proposed explanations include receptor desensitisation under chronic agonism, opposing roles in different tissues, and effects mainly on tolerability of the GLP-1 component.

What is new about the 2026 study?

It compared both directions in one model under matched conditions, rather than inferring across separate trials of separate compounds.

Does it resolve the question?

No. It is a mouse study, and rodent incretin physiology differs from human. It narrows the hypotheses rather than choosing between clinical strategies.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.